Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial
| Autor: | Jinping Zheng, Chunxue Bai, Jian Kang, Marco Sardina, Nanshan Zhong, Xia Li, Bai-Song Wang, Yi Gao, Huan-Ying Wan, Lijun Ma, Fuqiang Wen, Ping Chen, Wanzhen Yao, Luca Raiteri |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine China medicine.medical_specialty Exacerbation Vital Capacity Placebo-controlled study Placebo Drug Administration Schedule law.invention Pulmonary Disease Chronic Obstructive Double-Blind Method Randomized controlled trial law Forced Expiratory Volume Internal medicine medicine Clinical endpoint Humans Prospective Studies Adverse effect Aged Aged 80 and over COPD Dose-Response Relationship Drug business.industry Free Radical Scavengers Middle Aged medicine.disease Acetylcysteine Clinical trial Treatment Outcome Physical therapy Female business |
| Zdroj: | The Lancet Respiratory Medicine. 2:187-194 |
| ISSN: | 2213-2600 |
| DOI: | 10.1016/s2213-2600(13)70286-8 |
| Popis: | Summary Background Increased oxidative stress and inflammation has a role in the pathogenesis of chronic obstructive pulmonary disease (COPD). Drugs with antioxidant and anti-inflammatory properties, such as N-acetylcysteine, might provide a useful therapeutic approach for COPD. We aimed to assess whether N-acetylcysteine could reduce the rate of exacerbations in patients with COPD. Methods In our prospective, randomised, double-blind, placebo-controlled, parallel-group study, we enrolled patients aged 40–80 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV 1 ]/forced vital capacity 1 of 30–70% of predicted) at 34 hospitals in China. We stratified patients according to use of inhaled corticosteroids (regular use or not) at baseline and randomly allocated them to receive N-acetylcysteine (one 600 mg tablet, twice daily) or matched placebo for 1 year. The primary endpoint was the annual exacerbation rate in patients who received at least one dose of study drug and had at least one assessment visit after randomisation. This study is registered with the Chinese Clinical Trials Registry, ChiCTR-TRC-09000460. Findings Between June 25, 2009, and Dec 29, 2010, we screened 1297 patients, of whom 1006 were eligible for randomisation (504 to N-acetylcysteine and 502 to placebo). After 1 year, we noted 497 acute exacerbations in 482 patients in the N-acetylcysteine group who received at least one dose and had at least one assessment visit (1·16 exacerbations per patient-year) and 641 acute exacerbations in 482 patients in the placebo group (1·49 exacerbations per patient-year; risk ratio 0·78, 95% CI 0·67–0·90; p=0·0011). N-acetylcysteine was well tolerated: 146 (29%) of 495 patients who received at least one dose of N-acetylcysteine had adverse events (48 serious), as did 130 (26%) of 495 patients who received at least one dose of placebo (46 serious). The most common serious adverse event was acute exacerbation of COPD, occurring in 32 (6%) of 495 patients in the N-acetylcysteine group and 36 (7%) of 495 patients in the placebo group. Interpretation Our findings show that in Chinese patients with moderate-to-severe COPD, long-term use of N-acetylcysteine 600 mg twice daily can prevent exacerbations, especially in disease of moderate severity. Future studies are needed to explore efficacy in patients with mild COPD (GOLD I). Funding Hainan Zambon Pharmaceutical. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|